Latest news and press releases about Lipocine Inc. (LPCN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Price
| Price | $2.16 |
| Market Cap | $18M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.79 |
| EV / EBITDA | -1.23 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -64.75% |
| Return on Invested Capital | -57.74% |
| Return on Assets | -49.72% |
| Gross Margin | 98.10% |
| Operating Margin | -800.82% |
| Net Margin | -755.13% |
Related companies: ADAP · ANL · BLRX · EDSA · ERNA · GOVX · LNAI
Explore sector: Healthcare · Biotechnology
More sections of LPCN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks